monrd0010
Medals oligonucleic drug ID monrd0010
ATC Classification -
Product Name CpG 7909
Synonims AMA1-C1
PF-3512676
Country US
UK
Germany
Company Pfizer Inc
Ludwig Institute For Cancer Research
University of Oxford
Pfizer Pharma GmbH
phase III
Type CpG oligo
Adaptation Diseases matastatic or recurrent malignancies
advanced non-small cell lung cancer
Target Molecule TLR9
Remarks A phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma has been initiated.
On the other hand, a phase I/IIa trial of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/AlhydrogelR + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria has been initiated.
Nucleic Acid Sequence -
Source https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-003813-18/GB,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004686-15/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-004684-30/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-005389-11/GB,
https://www.clinicaltrialsregister.eu/ctr-search/search?query=CpG,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-004557-10/results,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001588-52/DE,
https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-001588-52/results
DrugBank -
TargetProtein - UniProt Q9NR96
TargetProtein - PDB 4QDH